About the AVAGLIO study in Western Australia

The AVAGLIO study is an international, multicentre, randomized, double blind, phase III study including over 900 patients with newly diagnosed histologically confirmed GBM which will investigate the efficacy and safety of treatment with AVASTIN combined with standard of care (temozolomide chemotherapy and radiotherapy) following surgery.(12) The AVAGLIO study is being conducted in 14 sites across Canada and a number of other sites around the world.

The primary endpoints of the AVAGLIO trial are progression-free survival, (defined as the duration for which a patient remains alive without their disease worsening) and overall survival.(12) Secondary endpoints that will be explored include one and two year survival rates, safety and health related quality of life.(12)

About AVASTIN

AVASTIN is an antibody that specifically binds and blocks the biological effects of VEGF (vascular endothelial growth factor). VEGF is the key driver of tumour angiogenesis - a fundamental process required for a tumour to grow and to spread (metastasize) to other parts of the body. AVASTIN'S precise mode of action allows it to be combined effectively with a broad range of chemotherapies and other anti-cancer treatments. AVASTIN helps to control tumour growth and extend survival with only a limited impact on the side effects of chemotherapy. Data from the comprehensive AVASTIN cancer clinical development programme have resulted in four approvals in Canada in advanced colorectal, breast, lung and brain cancer.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 81,500 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

    References

    1.  SEER Cancer Statistics Review (CSR), 1975-2006. Last accessed 4 March
        2010 at http://seer.cancer.gov/index.html
    2.  Medscape. Recurrent Glioblastoma Multiforme: Definition of Recurrent
        GBM. Last accessed 4 March 2010 at
        http://www.medscape.com/viewarticle/540150_2
    3.  Wong E et al. J Clin Oncol 1999; 17 (8): 2572-2578.
    4.  Ballman et al. Neuro Oncol 2007
    5.  Lamborn et al. Neuro Oncol 2008
    6.  Hart et al. Cochrane Database Syst Rev 2008
    7.  Fine et al. ASCO 2008
    8.  Friedman H et al. J Clin Oncol 2009; 31 August (Epub ahead of print
        as doi/10.1200/JCO.2008.19.8721) Last accessed 4 March 2010 at
        http://jco.ascopubs.org/cgi/content/abstract/JCO.2008.19.8721v1
    9.  Freidman et al. J Clin Oncol 1999; 17: 1516-1525.
    10. Cloughesy T et al. Cancer 2003; 97: 2381-2386.
    11. Vredenburgh J et al. ECCO 15 ESMO 34 2009; Abstract No.8707.
    12. Chinot, O. et al. ECCO 15 ESMO 34 2009; Poster No.46
    13. Stupp R et al. Ann Oncol 2007; 18 (supplement 2): ii69-ii70.
    14. Decision Resources, Cancer Incidence in 5 Continents Version IX, CI5
        IX, World Population Prospects, Central Brain Tumor Registry of the
        United States, National Swedish Brain Tumour Registry
    15. Takano S et al. Cancer Res 1996; 56: 2185-2190.
    16. Glioblastoma Multiforme - Treatment by Tumour Type. Canadian Cancer
        Society.
        http://info.cancer.ca/E/CCE/cceexplorer.asp?tocid=8.
        Accessed March 16, 2010.
    17. Canadian Cancer Statistics 2009. Canadian Cancer Society.
http://www.cancer.ca/~/media/CCS/Canada%20wide/Files%20List/English%20files%20heading/pdf%20not%20in%20publications%20section/Stats%202009E%20Cdn%20Cancer.ashx.
Accessed March 16, 2010.
    18. Avastin Canadian Product Monograph.